EB-101

BIOLOGICAL2 trials

Sponsors

Abeona Therapeutics, Inc

Conditions

Epidermolysis BullosaRDEBRecessive Dystrophic Epidermolysis Bullosa

Phase 3

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

CompletedNCT04227106

Abeona Therapeutics, IncEpidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa

Start: 2020-01-10End: 2022-10-18Updated: 2022-12-05

Unknown Phase

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

Enrolling by invitationNCT05708677

Abeona Therapeutics, IncRDEB

Start: 2021-02-09End: 2036-08-01Target: 22Updated: 2026-07-17

Related Papers

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.

2025-06-2310 citations

Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.

2022-10-1728 citations